South Texas Cancer Burden and COE Areas of Work
South Texas Cancer Burden and COE Areas of Work
South Texas Cancer Burden and COE Areas of Work
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).
About Cancer Clinical Trials
Cancer Genetics Program
Patient and Family Services During Cancer Care
Community Outreach and Engagement
Manage Your Cancer Risk
Blood Disorder (Hematology) Program